BRPI0417530A - liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração - Google Patents

liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração

Info

Publication number
BRPI0417530A
BRPI0417530A BRPI0417530-1A BRPI0417530A BRPI0417530A BR PI0417530 A BRPI0417530 A BR PI0417530A BR PI0417530 A BRPI0417530 A BR PI0417530A BR PI0417530 A BRPI0417530 A BR PI0417530A
Authority
BR
Brazil
Prior art keywords
need
penetration enhancers
adhesive
gestodene
hormones
Prior art date
Application number
BRPI0417530-1A
Other languages
English (en)
Inventor
Stefan Bracht
Michael Dittgen
Petra Huber
Thomas Langguth
Dirk Schenk
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34702342&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0417530(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0417530A publication Critical patent/BRPI0417530A/pt
Publication of BRPI0417530B1 publication Critical patent/BRPI0417530B1/pt
Publication of BRPI0417530B8 publication Critical patent/BRPI0417530B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7076—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising ingredients of undetermined constitution or reaction products thereof, e.g. rosin or other plant resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

"LIBERAçãO TRANSDéRMICA DE HORMÈNIOS SEM A NECESSIDADE DE MELHORADORES DE PENETRAçãO". A presente invenção refere-se a um curativo adesivo compreendendo uma camada contendo droga com um baixo teor de hormónios, como gestodene, e opcionalmente um estrogênio (por exemplo etinilestradiol). Quando da administração de um curativo adesivo a uma mulher, os níveis no plasma de pelo menos 1,0 ng/ml de Gestodene são obtidos em condições estáveis sem a necessidade de incorporar melhoradores de penetração ou melhoradores de permeação na camada contendo droga. De modo satisfatório, os níveis no plasma dos hormónios é também obtido em todo um período de pelo menos 1 semana, tornando o curativo adesivo aplicável para ser usado em contracepção feminina com o conceito de administração dos curativos adesivos semanalmente.
BRPI0417530A 2003-12-12 2004-12-10 composição para a liberação transdérmica de hormônios sem a necessidade de melhoradores de penetração, sistema terapêutico transdérmico, e kit BRPI0417530B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US52871803P 2003-12-12 2003-12-12
US60/528,718 2003-12-12
EP03078881 2003-12-12
EP03078881.4 2003-12-12
PCT/IB2004/052752 WO2005058287A2 (en) 2003-12-12 2004-12-10 Transdermal delivery system of hormones without penetration enhancers

Publications (3)

Publication Number Publication Date
BRPI0417530A true BRPI0417530A (pt) 2007-03-13
BRPI0417530B1 BRPI0417530B1 (pt) 2018-01-23
BRPI0417530B8 BRPI0417530B8 (pt) 2021-05-25

Family

ID=34702342

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417530A BRPI0417530B8 (pt) 2003-12-12 2004-12-10 composição para a liberação transdérmica de hormônios sem a necessidade de melhoradores de penetração, sistema terapêutico transdérmico, e kit

Country Status (15)

Country Link
JP (1) JP4965263B2 (pt)
KR (1) KR101168449B1 (pt)
CN (1) CN1913878B (pt)
AU (1) AU2004298930B2 (pt)
BR (1) BRPI0417530B8 (pt)
CA (1) CA2549916C (pt)
CU (1) CU23868B1 (pt)
EA (1) EA011160B1 (pt)
EC (1) ECSP066694A (pt)
IL (1) IL176112A (pt)
MX (1) MXPA06006682A (pt)
NO (1) NO341989B1 (pt)
NZ (1) NZ548091A (pt)
WO (1) WO2005058287A2 (pt)
ZA (1) ZA200605713B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2515918C (en) 2003-02-21 2010-11-16 Schering Ag Uv stable transdermal therapeutic plaster
US8962013B2 (en) 2005-05-02 2015-02-24 Bayer Intellectual Property Gmbh Multi-layered transdermal system with triazine UV absorber
DE102005050729A1 (de) * 2005-10-19 2007-04-26 Schering Ag Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption
FR2900048B1 (fr) * 2006-04-21 2012-11-16 Oreal Compositions comprenant un derive diphenyl-methane hydroxyle
DK2613772T3 (en) 2010-09-06 2017-03-06 Bayer Ip Gmbh TRANSDERMAL LOW DOSAGE PATTERNS WITH HIGH PHARMACEUTICAL RELEASE
AU2015203180B2 (en) * 2010-09-06 2016-06-30 Bayer Intellectual Property Gmbh Transdermal therapeutic systems with crystallization-inhibiting protective film (release liner)
DE102010040299A1 (de) * 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
JP6345120B2 (ja) * 2012-01-27 2018-06-20 アジル・セラピューティクス・インコーポレイテッドＡｇｉｌｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 経皮ホルモン送達
BR112017024783A2 (pt) * 2015-05-18 2018-08-07 Agile Therapeutics Inc composições contraceptivas e métodos para eficácia melhorada e modulação dos efeitos colaterais

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3238389B2 (ja) * 1988-10-27 2001-12-10 シエーリング アクチエンゲゼルシヤフト ゲストデン含有の経皮適用のための薬剤
MX9101787A (es) * 1990-10-29 1992-06-05 Alza Corp Formulaciones,metodos y dispositivos anticonceptivos transdermicos
US5512292A (en) * 1990-10-29 1996-04-30 Alza Corporation Transdermal contraceptive formulations methods and devices
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
EP0787488A4 (en) * 1994-11-18 1998-06-03 Hisamitsu Pharmaceutical Co TRANSDERMAL ABSORBABLE PLASTER
IL122432A (en) * 1995-06-07 2000-07-16 Cygnus Therapeutic Systems Transdermal patch for preventing ovulation
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
JP4167750B2 (ja) * 1997-04-16 2008-10-22 久光製薬株式会社 経皮吸収用基剤及び該基剤を含有する経皮吸収製剤
JP4399044B2 (ja) * 1998-10-14 2010-01-13 久光製薬株式会社 吸収促進剤及び該吸収促進剤を有してなる経皮吸収製剤
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
EP1197212A4 (en) * 1999-07-01 2004-06-02 Hisamitsu Pharmaceutical Co ADHESIVE COMPOSITION FOR PERCUTANE ABSORPTION
DE10053375C1 (de) * 2000-10-27 2002-01-24 Lohmann Therapie Syst Lts Transdermale therapeutische Systeme mit lichtempfindlichen Wirkstoffen
WO2002045701A2 (en) * 2000-12-05 2002-06-13 Noven Pharmaceuticals, Inc. Crystallization inhibition of drugs in transdermal drug delivery systems

Also Published As

Publication number Publication date
CU23868B1 (es) 2013-03-27
WO2005058287A3 (en) 2006-03-02
ECSP066694A (es) 2006-10-31
IL176112A0 (en) 2006-10-05
JP2007513938A (ja) 2007-05-31
MXPA06006682A (es) 2006-08-11
AU2004298930B2 (en) 2009-11-26
JP4965263B2 (ja) 2012-07-04
IL176112A (en) 2011-02-28
AU2004298930A1 (en) 2005-06-30
CN1913878B (zh) 2010-05-26
ZA200605713B (en) 2008-01-08
NO341989B1 (no) 2018-03-12
BRPI0417530B1 (pt) 2018-01-23
KR101168449B1 (ko) 2012-07-25
NZ548091A (en) 2009-12-24
KR20060128910A (ko) 2006-12-14
CA2549916A1 (en) 2005-06-30
CN1913878A (zh) 2007-02-14
WO2005058287A2 (en) 2005-06-30
NO20062594L (no) 2006-07-10
EA200601089A1 (ru) 2006-12-29
CA2549916C (en) 2013-09-17
BRPI0417530B8 (pt) 2021-05-25
EA011160B1 (ru) 2009-02-27
CU20100143A7 (es) 2011-10-31

Similar Documents

Publication Publication Date Title
MY152750A (en) Transdermal delivery system of hormones without penetration enhancers
US4863738A (en) Skin permeation enhancer compositions using glycerol monooleate
US4788062A (en) Transdermal administration of progesterone, estradiol esters, and mixtures thereof
HUP0402213A2 (hu) Propilénglikolmonokaprilátot tartalmazó szteroid hormontartalmú transzdermális terápiás rendszer
KR910700044A (ko) 에스트로겐/프로게스틴 경피용량 단위, 시스템 및 방법
KR900005969A (ko) 게스토덴을 함유하는 경피 투여용 제제
PT836506E (pt) Penso transdermico para administracao de 17-desacetil norgestimato so ou em combinacao com um estrogenio
DK1089722T3 (da) Transdermalt plaster af matrixtypen til steroidhormoner
BRPI0417530A (pt) liberação transdérmica de hormÈnios sem a necessidade de melhoradores de penetração
US20070077269A1 (en) Method of birth control and hormone regulation
BR0107881A (pt) Uso de fsh tratamento de infertilidade
BR0013711A (pt) Mesoprogestinas (moduladores de receptores de progesterona) como um componente de contraceptivos femininos
KR100550889B1 (ko) 스테로이드 함유 플라스터, 그 제조 방법, 및 그 용도
JP2000309526A (ja) とびひ治療貼付剤
CU23649B7 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
KR890014118A (ko) 골다공증 치료
WO2000059447A3 (fr) Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
UY28668A1 (es) Hormonas de administración transdérmica que no necesitan potenciadores de penetración
TH115856B (th) การนำส่งฮอร์โมนผ่านผิวหนังโดยไม่ต้องการสารเพิ่มการแทรกซึม
KR950002749A (ko) 0차 흡수속도를 갖는 지속성 경피투여 제형 및 그 제조방법

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/70, A61K 31/565, A61P 15/00

Ipc: A61K 9/70 (2011.01), A61K 31/565 (2011.01)

B25D Requested change of name of applicant approved

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE)

Free format text: NOME ALTERADO DE: SCHERING AKTIENGESELLSCHAFT

B25D Requested change of name of applicant approved

Owner name: BAYER PHARMA AKTIENGESELLSCHAFT (DE)

B25A Requested transfer of rights approved

Owner name: BAYER INTELLECTUAL PROPERTY GMBH. (DE)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/12/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2700 DE 04-10-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.